click below
click below
Normal Size Small Size show me how
IOS 11 Exam 2
Immunomodulators
| Question | Answer |
|---|---|
| Different types of immunity that can be conferred to humans | Vaccines- Live or attenuated, Toxoids0inactivated toxins, Immune globulins-antibodes from animals or humans |
| active immunity characteristics | Detection of antibosies in 7-10d, Mostly permanent immunity, can not be inhibited by passive immunity, may not be effective in immune compromised |
| Immune globulins are | antibodies that are from external suorce, animals or human sera |
| Human sera is | prefered due to less Type III it is pooled from 3000-20,000 to make 1 lot of IgG (90%), trace IgM, IgA, and other plasma proteins |
| Immune globulins MOA | Antibodies neutralize or eliminate pathogenic of toxic molecules or cause compliment medited cytotoxcity half life is 18-32 days |
| Passive immunity acts | Immediately as a temporary immunity (days-weeks) with a specif Immunoglobulin |
| IMIG Non-specific coverage | Gamastan, Gammar |
| IMIG specific coverage | Hep B, varicella-zoster,vaccinia,rabies,tetanus |
| IVIG specific coverage | RSV,CMV |
| IVIG no-specific coverage | polygam, Gammagard,Gamimune,Carimune,Octagam, gamunex |
| Immune globulin therapy is derived from high titers of | specific IgG from plasma pools and obtained from immunized donors- it will have a high affinity for pathogenic antigens |
| Non-specific IM & IV immune globulins have coverage over | Herpes 1,2,6, 7, varicella zoster, Epstein-barr, measles, mumps, rubella, parvovirus B19, bacteria-mycoplasma pneumonia, chlymadia pneumomia, helicobacter pylori, tetanus |
| Non-speci IVIG FDA indications | Primary immunodeficiency, immune thrombocytopenic purpura, chronic lymphocytic leukemia, kawasaki disease, bone marrow transplant |
| OFF labels uses for immune globulins | Neonatal sepsis, Guille Barre, autoimmune diseases, intractable epilepsy, chronic inflammatory demyelination polyneuropathy, SLE |
| IMIG adeverse effects include | Injection site pain, tenderness, muscle stiffness |
| IVIG adverse effects include | (infusion)-chills, fever, hypotension- Management- slow rate, tylenol, benedryl, or dilute |
| General consequences of to much IgG | ARF, Hematologic neutropenia, coronary thrombosis, Neurologic -aseptic meningitis, Dermatologic, Infectious disease transmission |
| IVIG has a higher utilization in | Canada than in the US but there has been a 20% increase per year it is $70/gram |
| IVIG administration | Start at 0.6mL/kg/hr x 30minutes, if tolerates increase to 1.2mL/kg/hrx 30, if tolerates increase to 2.4mL/kg/hrx 30min, if tolerates increase to 4mL/kg/hr until entire volume is inserted into patient |